B[Afternoon session of the third day of the 2026 National Talks: BeiGene, Colombotel, Roche, and Daiichi Sankyo will appear] September 7th, at about 13:00 today, the third day of the 2026 National Basic Medical Insurance Drug List Negotiation and Bidding and the Commercial Insurance Innovative Drug List Price Negotiation will begin. The midday session started. Reporters observed at the scene that domestic and foreign companies such as Colombotech, BeiGene, Roche, AstraZeneca, Hengrui Pharmaceuticals, Daiichi Sankyo, Novartis, Pierre Fabre, Sanofi, Bristol-Myers Squibb, Pfizer, etc. entered the negotiation room, and about 20 companies were negotiating. (Reporters Lu Afeng and Yu Miao) B[The agenda of the first day of the 2026 national talks ended at 6 p.m. Chairman of Tonghua Jinma and Dongguang Pharmaceutical personally participated in the battle] On September 5, reporters learned from the on-site negotiation of the 2026 National Medical Insurance Catalog and the price negotiation of the commercially insured innovative drug catalog that the agenda of the first day of the national talks ended at around 6 p.m. The reporter noticed that in the afternoon session, representatives from a number of GLP-1 hypoglycemic drugs that had passed the preliminary review were gathered together, which may mean that the track is ushering in intensive negotiations, including Innovent Biologics’ Masidutide, Pfizer’s Enoglutide Injection, etc. Chairman Zhang Yufu personally participated in the negotiations for Tonghua Jinma's new Alzheimer's drug Avicridine Succinate Tablets. He left with a smile after completing the negotiations. Zhang Yingjun, chairman of Dongyangguang Pharmaceutical, also led a team to participate in the on-site negotiations. The last company representative to leave the afternoon session was from Simcere Pharmaceuticals. The company's new insomnia drug Dalilaysan Hydrochloride Tablets are on the preliminary review list for national negotiation and commercial insurance for innovative drugs. In addition, the acute ischemic stroke drug Edaravone Dexbobornol Sublingual Tablets and others have passed the preliminary review. In addition, the reporter noticed that the overall expression of corporate representatives in the afternoon session was relatively serious after appearing. (Reporters Lu Afeng and Yu Miao) B[Afternoon session of the first day of the 2026 National Talks: Representatives from Hengrui Pharmaceuticals, Dongguang Pharmaceutical, Pfizer and other companies entered the venue to start negotiations on chronic disease varieties] The reporter learned from the on-site negotiation of the 2026 National Medical Insurance Catalog and the price negotiation of the commercially insured innovative drug catalog that the afternoon session of the first day of the National Talks started at about 13:00 today. Reporters observed at the scene that negotiators from Hengrui Pharmaceuticals, Dongguang Pharmaceutical, Pfizer, Novo Nordisk, Tonghua Jinma and other companies successively arrived at the National People's Congress Conference Center in Beijing and entered the venue one after another after accepting identity verification. According to incomplete statistics from reporters, about 20 companies participated in negotiations during the afternoon session. Among them, Dongguangguang Pharmaceutical’s ologliflozin and hepatitis C combination drugs natansvir phosphate and icofosbuvir tablets, Pfizer’s new dual-indication drug for weight loss and diabetes, enoglutide injection and ogaituzumab for injection, and Tonghua Jinma’s new Alzheimer’s disease drug Aviacridine succinate tablets have all passed the preliminary review, which also means that innovative drugs and chronic disease drugs have begun intensive negotiations. (Reporters Lu Afeng and Yu Miao) B[In the afternoon of the first day of the 2026 National Talks: Pfizer, Innovent Biologics and many other Chinese and foreign companies entered the venue] "Science and Technology Innovation Board Daily" reported on the 5th that the negotiations on the 2026 National Medical Insurance Catalog officially started today. A reporter from "Science and Technology Innovation Board" learned at the scene that at about 1:15 p.m., people entered the venue Companies include Hengrui Pharmaceuticals, Dongguang Pharmaceutical, Zhuhai Rundu Pharmaceuticals, CSPC Pharmaceutical Group, Shanghai Pharmaceuticals, Innovent Biologics, Jingxin Pharmaceuticals, Boehringer Ingelheim, Novo Nordisk, Pfizer, etc. Companies entering the market this morning include Genting Xinyao, Zai Lab, 3SBio, Joincare, Kangyuan Pharmaceuticals, etc. (Kechuangban Daily reporter Shi Shiyun)
— All loaded —
